CalciMedica

CalciMedica

CalciMedica is a clinical-stage biotechnology company based in La Jolla, California, developing therapeutics that target CRAC channels to treat inflammatory and autoimmune conditions. The company originated from research at the Sanford-Burnham Medical Research Institute, with foundational work by Drs. Kenneth Stauderman and others on calcium signaling. Its core platform centers on small-molecule inhibitors of CRAC channels, which regulate calcium influx in immune cells. CalciMedica's primary asset is Auxora, a CRAC channel inhibitor that has been evaluated in acute pancreatitis, COVID-19-associated pneumonia, and acute lung injury. In December 2023, the company reported positive top-line results from its Phase 2b KOURAGE trial for acute pancreatitis, meeting the primary endpoint of reduced systemic inflammation. The firm also explores applications in cytokine release syndrome and chronic inflammatory diseases, with preclinical programs targeting autoimmune conditions. The company operates as a public entity, trading on the Nasdaq under the ticker CALC, after merging alum Capital in October 2023. This SPAC merger provided approximately $27 million in gross proceeds to fund operations into 2024. CalciMedica maintains a lean operational structure with a small team focused on clinical development and regulatory affairs. CalciMedica's structural differentiator lies in its targeting of CRAC channels, a specific ion channel pathway that governs calcium signaling in immune cells. This approach is upstream of many cytokine-mediated inflammatory responses, potentially offering broader efficacy than agents targeting individual cytokines. The company's ability to advance through Phase 2b with a novel mechanism positions it distinctively among biotech firms developing anti-inflammatory therapeutics.